Parties seeking to nominate themselves as potential panelists in the workshop must notify the FTC in writing of their interest in participating on or before Wednesday, April 12, 2006. Requests to participate as workshop panelists should refer to "Mortgage Workshop—Panelist Participation Request." A request to participate filed in paper form should include this reference both in the text and on the envelope, and should be mailed or delivered to the following address: Mortgage Workshop, c/o Julie Bush, FTC, 601 New Jersey Avenue, NW., Mail Stop NJ-3158, Washington, DC 20580. If the request to participate contains any material for which confidential treatment is requested, it must be filed in paper (rather than electronic) form, and the first page of the document must be clearly labeled "Confidential." The FTC prefers that any request to participate filed in paper form be sent by courier or overnight service, if possible, because U.S. postal mail in the Washington area is subject to delay due to heightened security precautions. Please include an original and two copies of each document submitted in paper form.

In the alternative, parties may e-mail requests to participate as workshop panelists (except requests containing any confidential material) to mortgageworkshop@ftc.gov and should caption them: "Mortgage Workshop—Panelist Participation Request."

Requests to participate as workshop panelists should include the following information:

- (1) A brief biographical description, including name and affiliation;
- (2) A statement setting forth the potential panelist's expertise in or knowledge of one or more issues likely to be addressed by the workshop;
- (3) A list of the topic(s) that the potential panelist would like to address, and a one-paragraph summary of the potential panelist's unique perspective or knowledge of each such topic; and
- (4) Contact information, including a daytime telephone number, facsimile number, and e-mail address (if available).

Parties filing requests to participate as workshop panelists will be notified

whether they have been invited on or before Wednesday, April 26, 2006.

The FTC Act and other laws the Commission administers permit the collection of requests to participate as workshop panelists, to consider and use in this proceeding as appropriate. More information, including routine uses permitted by the Privacy Act, may be found in the FTC's privacy policy, at <a href="http://www.ftc.gov/ftc/privacy/htm">http://www.ftc.gov/ftc/privacy/htm</a>.

## **General Participation**

The event is open to the public and there is no fee for attendance. For admittance to the workshop, all attendees will be required to show a valid form of photo identification, such as a driver's license.

By direction of the Commission.

## Donald S. Clark,

Secretary.

[FR Doc. E6–4439 Filed 3–27–06; 8:45 am] BILLING CODE 6750–01–P

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

**Food and Drug Administration** 

[Docket No. 2005N-0395]

Agency Information Collection Activities; Announcement of Office of Management and Budget Approval; Guidance for Industry on Formal Meetings With Sponsors and Applicants for Prescription Drug User Fee Act Product

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing that a collection of information entitled "Guidance for Industry on Formal Meetings With Sponsors and Applicants for Prescription Drug User Fee Act Product" has been approved by the Office of Management and Budget (OMB) under the Paperwork Reduction Act of 1995.

### FOR FURTHER INFORMATION CONTACT:

Karen Nelson, Office of Management Programs (HFA–250), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301–827–1482.

**SUPPLEMENTARY INFORMATION:** In the **Federal Register** of January 24, 2006 (71 FR 3858), the agency announced that the proposed information collection had been submitted to OMB for review and clearance under 44 U.S.C. 3507. An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it

displays a currently valid OMB control number. OMB has now approved the information collection and has assigned OMB control number 0910–0429. The approval expires on March 31, 2009. A copy of the supporting statement for this information collection is available on the Internet at <a href="http://www.fda.gov/ohrms/dockets">http://www.fda.gov/ohrms/dockets</a>.

Dated: March 20, 2006.

#### Jeffrey Shuren,

Assistant Commissioner for Policy.
[FR Doc. E6–4424 Filed 3–27–06; 8:45 am]
BILLING CODE 4160–01–8

# DEPARTMENT OF HEALTH AND HUMAN SERVICES

**Food and Drug Administration** 

[Docket No. 2005N-0507]

Agency Information Collection
Activities; Announcement of Office of
Management and Budget Approval;
Guidance on Informed Consent for In
Vitro Diagnostic Device Studies Using
Leftover Human Specimens That are
Not Individually Identifiable

**AGENCY:** Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing that a collection of information entitled "Guidance on Informed Consent for *In Vitro* Diagnostic Device Studies Using Leftover Human Specimens That are Not Individually Identifiable" has been approved by the Office of Management and Budget (OMB) under the Paperwork

#### FOR FURTHER INFORMATION CONTACT:

Reduction Act of 1995.

Karen L. Nelson, Office of Management Programs (HFA–250), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301–827–1482.

SUPPLEMENTARY INFORMATION: In the Federal Register of January 9, 2006 (71 FR 1429), the agency announced that the proposed information collection had been submitted to OMB for review and clearance under 44 U.S.C. 3507. An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control number. OMB has now approved the information collection and has assigned OMB control number 0910-0582. The approval expires on September 30, 2006. A copy of the supporting statement for this information collection is available on the Internet at http:// www.fda.gov/ohrms/dockets.

¹Commission Rule 4.2(d), 16 CFR 4.2(d). The request to participate must be accompanied by an explicit request for confidential treatment, including the factual and legal basis for the request, and must identify the specific portions of the request to participate to be withheld from the public record. The request for confidential treatment will be granted or denied by the Commission's General Counsel, consistent with applicable law and the public interest. See Commission Rule 4.9(c), 16 CFR 4.9(c).